ArticleJournal of circulating biomarkers
Circulatory biomarkers for microbial infections.
Article in Journal of circulating biomarkers. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article explores the paradigm shift in infectious disease diagnostics from direct pathogen detection to host-response profiling. While traditional markers like C-reactive protein (CRP) and procalcitonin (PCT) are clinical staples, they lack the specificity required for precision antimicrobial stewardship. The perspective highlights the emergence of presepsin as a superior early-phase bacterial biomarker and the development of multi-parametric mRNA signatures that differentiate viral from bacterial etiologies with high sensitivity. Furthermore, the expansion into pan-microbial surveillance, incorporating fungal (BDG, Galactomannan) and protozoal (HRP2/pLDH) markers, addresses critical blind spots in empiric therapy. Despite challenges regarding cost and standardization, the integration of these circulatory biomarkers with AI-driven decision support is poised to slowly replace empiric treatment with precision stewardship. This transition enables the triangulation of infection etiology within the clinical "golden hour", ultimately improving patient outcomes and combating antibiotic resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.